Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis

Sonja Holm-Yildiz; Tina Dysgaard; Thomas Krag; Britt Stævnsbo Pedersen; Sebastian Rask Hamm; Laura Pérez-Alós; Cecilie Bo Hansen; Mia Marie Pries-Heje; Line Dam Heftdal; Rasmus Bo Hasselbalch; Kamille Fogh; Johannes Roth Madsen; Ruth Frikke-Schmidt; Linda Maria Hilsted; Erik Sørensen; Sisse Rye Ostrowski; Henning Bundgaard; Peter Garred; Kasper Iversen; Susanne Dam Nielsen; John Vissing

doi:10.1016/j.jneuroim.2023.578215

Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis

Sonja Holm-Yildiz^*, Tina Dysgaard, Thomas Krag, Britt Stævnsbo Pedersen, Sebastian Rask Hamm, Laura Pérez-Alós, Cecilie Bo Hansen, Mia Marie Pries-Heje, Line Dam Heftdal, Rasmus Bo Hasselbalch, Kamille Fogh, Johannes Roth Madsen, Ruth Frikke-Schmidt, Linda Maria Hilsted, Erik Sørensen, Sisse Rye Ostrowski, Henning Bundgaard, Peter Garred, Kasper Iversen, Susanne Dam NielsenJohn Vissing

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

2 Citationer (Scopus)

17 Downloads (Pure)

Abstract

We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).

Originalsprog	Engelsk
Artikelnummer	578215
Tidsskrift	Journal of Neuroimmunology
Vol/bind	384
Antal sider	5
ISSN	0165-5728
DOI	https://doi.org/10.1016/j.jneuroim.2023.578215
Status	Udgivet - 2023

Bibliografisk note

Funding Information:
This work was financially supported by UCB . The control program was financially supported by the Carlsberg Foundation ( CF20–476 0045 , granted to PG), the Novo Nordisk Foundation ( NFF205A0063505 and NNF20SA0064201 , granted to PG), and the Svend Andersen Research Foundation ( SARF2021 , granted to PG). The grant bodies were not involved in any part of the study design, data collection, data analysis, interpretation of the data or the writing of this manuscript.

Publisher Copyright:
© 2023 The Authors

Adgang til dokumentet

10.1016/j.jneuroim.2023.578215Licens: CC BY

FulltextForlagets udgivne version, 571 KBLicens: CC BY

Citationsformater

Holm-Yildiz, S., Dysgaard, T., Krag, T., Pedersen, B. S., Hamm, S. R., Pérez-Alós, L., Hansen, C. B., Pries-Heje, M. M., Heftdal, L. D., Hasselbalch, R. B., Fogh, K., Madsen, J. R., Frikke-Schmidt, R., Hilsted, L. M., Sørensen, E., Ostrowski, S. R., Bundgaard, H., Garred, P., Iversen, K., ... Vissing, J. (2023). Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis. Journal of Neuroimmunology, 384, [578215]. https://doi.org/10.1016/j.jneuroim.2023.578215

Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis. / Holm-Yildiz, Sonja; Dysgaard, Tina; Krag, Thomas; Pedersen, Britt Stævnsbo; Hamm, Sebastian Rask; Pérez-Alós, Laura; Hansen, Cecilie Bo; Pries-Heje, Mia Marie; Heftdal, Line Dam; Hasselbalch, Rasmus Bo; Fogh, Kamille; Madsen, Johannes Roth; Frikke-Schmidt, Ruth; Hilsted, Linda Maria; Sørensen, Erik; Ostrowski, Sisse Rye ; Bundgaard, Henning ; Garred, Peter ; Iversen, Kasper ; Nielsen, Susanne Dam ; Vissing, John.

I: Journal of Neuroimmunology, Bind 384, 578215, 2023.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Holm-Yildiz, S, Dysgaard, T, Krag, T, Pedersen, BS, Hamm, SR, Pérez-Alós, L, Hansen, CB, Pries-Heje, MM, Heftdal, LD, Hasselbalch, RB, Fogh, K, Madsen, JR, Frikke-Schmidt, R, Hilsted, LM, Sørensen, E, Ostrowski, SR , Bundgaard, H , Garred, P , Iversen, K , Nielsen, SD & Vissing, J 2023, 'Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis', Journal of Neuroimmunology, bind 384, 578215. https://doi.org/10.1016/j.jneuroim.2023.578215

Holm-Yildiz, Sonja ; Dysgaard, Tina ; Krag, Thomas ; Pedersen, Britt Stævnsbo ; Hamm, Sebastian Rask ; Pérez-Alós, Laura ; Hansen, Cecilie Bo ; Pries-Heje, Mia Marie ; Heftdal, Line Dam ; Hasselbalch, Rasmus Bo ; Fogh, Kamille ; Madsen, Johannes Roth ; Frikke-Schmidt, Ruth ; Hilsted, Linda Maria ; Sørensen, Erik ; Ostrowski, Sisse Rye ; Bundgaard, Henning ; Garred, Peter ; Iversen, Kasper ; Nielsen, Susanne Dam ; Vissing, John. / Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis. I: Journal of Neuroimmunology. 2023 ; Bind 384.

@article{7049852bfd63438ba441f6145b1fb02d,

title = "Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis",

abstract = "We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).",

keywords = "BNT162b2, COVID-19 vaccine, Humoral response, Myasthenia gravis",

author = "Sonja Holm-Yildiz and Tina Dysgaard and Thomas Krag and Pedersen, {Britt St{\ae}vnsbo} and Hamm, {Sebastian Rask} and Laura P{\'e}rez-Al{\'o}s and Hansen, {Cecilie Bo} and Pries-Heje, {Mia Marie} and Heftdal, {Line Dam} and Hasselbalch, {Rasmus Bo} and Kamille Fogh and Madsen, {Johannes Roth} and Ruth Frikke-Schmidt and Hilsted, {Linda Maria} and Erik S{\o}rensen and Ostrowski, {Sisse Rye} and Henning Bundgaard and Peter Garred and Kasper Iversen and Nielsen, {Susanne Dam} and John Vissing",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

doi = "10.1016/j.jneuroim.2023.578215",

language = "English",

volume = "384",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

TY - JOUR

T1 - Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis

AU - Holm-Yildiz, Sonja

AU - Dysgaard, Tina

AU - Krag, Thomas

AU - Pedersen, Britt Stævnsbo

AU - Hamm, Sebastian Rask

AU - Pérez-Alós, Laura

AU - Hansen, Cecilie Bo

AU - Pries-Heje, Mia Marie

AU - Heftdal, Line Dam

AU - Hasselbalch, Rasmus Bo

AU - Fogh, Kamille

AU - Madsen, Johannes Roth

AU - Frikke-Schmidt, Ruth

AU - Hilsted, Linda Maria

AU - Sørensen, Erik

AU - Ostrowski, Sisse Rye

AU - Bundgaard, Henning

AU - Garred, Peter

AU - Iversen, Kasper

AU - Nielsen, Susanne Dam

AU - Vissing, John

PY - 2023

Y1 - 2023

N2 - We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).

AB - We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).

KW - BNT162b2

KW - COVID-19 vaccine

KW - Humoral response

KW - Myasthenia gravis

U2 - 10.1016/j.jneuroim.2023.578215

DO - 10.1016/j.jneuroim.2023.578215

M3 - Journal article

C2 - 37797472

AN - SCOPUS:85172764956

VL - 384

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

M1 - 578215

ER -